<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03754309</url>
  </required_header>
  <id_info>
    <org_study_id>KY1005-CT02</org_study_id>
    <secondary_id>2018-002299-41</secondary_id>
    <nct_id>NCT03754309</nct_id>
  </id_info>
  <brief_title>A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis</brief_title>
  <official_title>A Phase 2a, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study of an Anti OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kymab Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kymab Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to investigate if KY1005 results in improvement of&#xD;
      eczema when given to participants with moderate to severe disease. Side effects of KY1005&#xD;
      will also be explored.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the efficacy,&#xD;
      safety and tolerability of two doses of KY1005 in adults with moderate to severe atopic&#xD;
      dermatitis whose disease cannot be adequately controlled with topical medications or for whom&#xD;
      topical treatment is medically inadvisable.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2018</start_date>
  <completion_date type="Actual">October 8, 2020</completion_date>
  <primary_completion_date type="Actual">May 12, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Primary analysis up to day 113. Long term follow up to day 253 (dependent on response).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>Baseline to day 113</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Baseline to day 113</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage and absolute change from Baseline in EASI over time</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in epidermal thickness</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in keratin 16 staining of skin biopsies</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with at least a 50% reduction in EASI (EASI 50)</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with at least a 75% reduction in EASI (EASI 75)</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with at least a 90% reduction in EASI (EASI 90)</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Validated Investigator Global Assessment (vIGA)</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a response of vIGA 0 or 1</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SCORing of Atopic Dermatis (SCORAD) Index</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in affected body surface area (BSA)</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Orientated Eczema Measure (POEM)</measure>
    <time_frame>Baseline to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Orientated SCORing of Atopic Dermatitis (PO-SCORAD) Index</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dermatology Quality of Life Index (DLQI)</measure>
    <time_frame>Baseline to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Numerical Rating Scale (NRS) for pruritus</measure>
    <time_frame>Baseline to day 113</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>KY1005 lower dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose KY1005</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KY1005 higher dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose KY1005</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KY1005</intervention_name>
    <description>A human anti-OX40 ligand monoclonal antibody</description>
    <arm_group_label>KY1005 higher dose</arm_group_label>
    <arm_group_label>KY1005 lower dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (≥ 18 years but &lt; 75 years of age) with Atopic Dermatitis (AD) for 1 year or&#xD;
             longer at Baseline (Day 1; prior to first administration of Investigational Medicinal&#xD;
             Product (IMP)).&#xD;
&#xD;
          -  EASI of 12 or higher at the Screening Visit and 16 or higher at Baseline.&#xD;
&#xD;
          -  vIGA of 3 or 4 at Baseline.&#xD;
&#xD;
          -  AD involvement of 10 percent or more of BSA at Baseline.&#xD;
&#xD;
          -  Documented history, within 6 months prior to Baseline, of either inadequate response&#xD;
             to topical treatments or inadvisability of topical treatments.&#xD;
&#xD;
          -  Must have applied a stable dose of topical bland emollient (simple moisturiser, no&#xD;
             additives [e.g., urea]) at least twice daily for at least 7 consecutive days before&#xD;
             Baseline.&#xD;
&#xD;
          -  Able and willing to comply with requested study visits/telephone visits and&#xD;
             procedures.&#xD;
&#xD;
          -  Able and willing to provide punch biopsy of both lesional and non-lesional skin at&#xD;
             Baseline.&#xD;
&#xD;
          -  Able and willing to provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent treatment within specific time windows before the baseline visit for the&#xD;
             management of atopic dermatitis such as topical or systemic corticosteroids, biologic&#xD;
             or investigational therapies and/or phototherapy.&#xD;
&#xD;
          -  Known history of or suspected significant current immunosuppression, including history&#xD;
             of invasive opportunistic infections despite infection resolution or otherwise&#xD;
             recurrent infections of abnormal frequency or prolonged duration.&#xD;
&#xD;
          -  Basal and squamous cell skin cancer in the last 3 years prior to Baseline. Any other&#xD;
             malignancies in the last 5 years prior to Baseline (excluding in situ cervical&#xD;
             carcinoma).&#xD;
&#xD;
          -  Severe concomitant illness that would in the Investigator's opinion inhibit the&#xD;
             patient's participation in the study, including for example, but not limited to, renal&#xD;
             disease, neurological conditions, heart failure and pulmonary disease.&#xD;
&#xD;
          -  Laboratory values at the Screening Visit:&#xD;
&#xD;
          -  a. Serum creatinine &gt; 1.6 mg/dL (141 μmol/L) in female patients and &gt; 1.9 mg/dL (168&#xD;
             μmol/L) in male patients;&#xD;
&#xD;
          -  b. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 1.5 × upper&#xD;
             limit of normal (ULN);&#xD;
&#xD;
          -  c. Platelet count &lt; 100 × 10^9/L;&#xD;
&#xD;
          -  d. Haemoglobin (Hb): Male &lt; 13.5g/dL and Female &lt;12g/dL;&#xD;
&#xD;
          -  e. White blood cell count (WBCC) &lt; 3.0 × 10^9/L;&#xD;
&#xD;
          -  f. Absolute neutrophil count &lt; 2.0 × 10^9/L;&#xD;
&#xD;
          -  g. Absolute lymphocyte count &lt; 0.5 × 10^9/L;&#xD;
&#xD;
          -  h. Total bilirubin &gt; ULN.&#xD;
&#xD;
          -  Participation in any other clinical study, including non-interventional studies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Weidinger, MaHM</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Schleswig-Holstein, 24105 Kiel, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kymab investigational site 106</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 113</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 207</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 216</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 206</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 212</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 213</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 214</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 203</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 210</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigator site 201</name>
      <address>
        <city>Rzeszow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 204</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 202</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 304</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 303</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 302</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 315</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 420</name>
      <address>
        <city>Harrogate</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kymab investigational site 402</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 19, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <disposition_first_submitted>April 30, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>April 30, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 4, 2021</disposition_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

